During the last decades, developing of safe and effective kidney-protective interventions to slow or stop the progression of established nephropathy is an important strategy in reducing the incidence of end stage renal disease. Thus, it is to be understood why many studies have focused on the investigation of molecules that could contribute to reducing proteinuria and to slowdown the progression of chronic kidney disease. Significant steps in this direction were made by introducing angiotensin-converting enzyme inhibitors (ACEIs) in 1993 and angiotensin receptor blockers (ARBs) in 2001, while other molecules like glycosaminoglycans (GAGs), despite promising data in experimental studies, are still gathering evidence of clinical applicability [1] .
Sulodexide (Vessel Due F, Alfa Wassermann S.p.A Bologna, Italy) is a natural structure, extract from mammalian intestinal mucosa, with a complex architecture including a highly purified mixture of GAGs, consisting in a fast moving heparin-like fraction: iduronilglucosaminilglycan sulphate (80%) and dermatan sulphate (20%); compared to standard heparin, sulodexide has a longer half-life, high oral bioavailability and reduced effect on systemic clotting and bleeding [2] . Sulodexide has proved beneficial cardiovascular effects explained by several pharmacological actions: (1) antithrombotic activity mainly through inhibition of intrinsic factor Xa activation (Sulodexide is the second most effective inhibitor of intrinsic factor Xa activation!) and accelerating the inhibition of thrombin by interacting with antithrombin III and heparin cofactor II; (2) fibrinolysis activation by increase of tissue plasminogen activator activity and by decrease of plasminogenic activator inhibitor-1; (3) tissue perfusion facilitation by prevention of vascular inflammatory injuries, possibly through the inhibition of complement activation and inhibition of C-reactive protein; (4) antilipemic and antiatherosclerotic effects by lipoprotein lipase release; (5) restoration of venous wall tonicity, via reduction/ inhibition of matrix metalloproteinases MMP-9 forms from leukocytes/platelets and inhibition of type IV collagen degradation; (6) restoration of vascular permeability by increase of the thickness of endothelial glycocalyx; (7) improvement of endothelium-dependent relaxation in arteries [3] [4] [5] [6] .
Moreover, experimental and clinical studies identified several mechanisms of action which can explain its potential benefit in renal diseases. Thus, Sulodexide has the capacity to replace lost endogenous heparan sulphate (HS) and to restore the anionic charges, both at vascular endothelial and glomerular cells levels. Restoration of HS in mesangial cells inhibits their proliferation, [7] and in podocytes contributes to restoration of glomerular basement membrane (GBM) permeability to albumin [8] . At extracellular level, Sulodexide precludes the extracellular matrix expansion and type III and type IV collagen deposition, by inhibition of the expression and bioactivity of transforming growth factor TGF-β1 [9] . Also, Sulodexide has the capacity to inhibit heparanase-1, preventing epithelial-mesenchymal transition and renal interstitial fibrosis induced via FGF-2 loop [10] . Therefore, preclinical and clinical evidence support the antiproteinuric and nephroprotective effects of GAGs and Sulodexide, justifying their administration not only in DN, but also in other chronic nephropathies [11] .
The aim of our study was to evaluate the efficacy of Sulodexide in different chronic nephropathies accompanied by proteinuria. We assessed Sulodexide capacity to contribute to a decrease in proteinuria, while preserving/improving the level of glomerular filtration rate.
MATERIAL AND METHODS

STUDY PATIENTS
We performed a prospective study in patients over 18 years with CKD caused by diabetes mellitus, primary hypertension or primary glomerulonephritis, hospitalized in our center between January 2010 and July 2012, and in whom treatment with oral Sulodexide (Vessel Due F) was started as decided by each patient's attending physician. Data were collected prospectively from the medical records of patients: demographics (age, gender), etiology of renal disease (diabetic nephropathy, hypertensive nephropathy and glomerular nephropathy), history of antihypertensive treatment (angiotensin converting enzyme inhibitors [ACEI], angiotensin receptor blockers [ARB], beta blockers, calcium channel blockers), clinical data (body mass index, systolic and diastolic blood pressure, heart rate) and laboratory parameters (serum creatinine, serum albumin, glycaemia, serum cholesterol and triglycerides, proteinuria; estimated GFR [eGFR] was calculated using the Chronic Kidney Disease Epidemiology Collaboration formula). Clinical and biological parameters were also recorded after 12 months of treatment with Sulodexide.
TREATMENT EFFICACY Low-dose of 50 mg/day Sulodexide was administered daily in all patients for 12 months. Patients with diabetes mellitus were under specific medication in order to control the glucose blood level and arterial blood pressure as decided by their physician; none of the patients with primary GN was on immunosuppressive therapy. During their long-term treatment (12 months) with Sulodexide, patients did not change their diet or the antidiabetic and antihypertensive therapy.
The primary indicator was the evolution of proteinuria after 12 months of treatment. Efficacy was calculated as proteinuria variation from baseline to the end of study, and evaluated in the study group and in subgroups by considering patients as responders or non-responders. Response was defined as a decline in proteinuria below 0.3 g/day. Time to response was defined as the treatment duration until a patient achieved the responder status. Additionally, the renal function evolution was evaluated as eGFR at the end of the study compared to baseline.
STATISTICAL ANALYSIS
Data were analyzed using the software package SPSS for Windows release 21. Baseline characteristics of groups were compared using independent samples t test, ANOVA and chi-squared test (for categorical data) and Mann-Whitney U test for non-parametrical data. A p value <0.05, 95% CI was considered statistically significant. We applied logarithmic transformation for proteinuria in order to improve the normal data distribution.
Paired-Samples T Test was used to determine whether there is a statistically significant difference between the pre-and post-treatment levels of proteinuria within study patients.
ANOVA and Bonferroni test for multiple comparisons were used to evaluate the percent reductions in baseline proteinuria at 12 months in each CKD group. As described by Gambaro et al. [12] , the percent reduction in proteinuria was calculated as
where ∆ is the difference in adjusted mean ln(proteinuria) at baseline and after 12 months of treatment with Vessel Due F.
Unadjusted response rates were studied using the Kaplan-Meier survival analysis based on logrank test. Cox regression analysis applying backward stepwise method was used to build a time-toresponse model adjusted for different explanatory variables.
RESULTS
A total of 100 patients were included in this analysis. The etiology of renal disease was DN in 58 patients (58%), GN in 25 patients (25%) and HN in 17 patients (17%).
Mean age was significantly lower in GN patients (44 ± 13 years) compared to diabetic (59 ± 11 years) and hypertensive (66 ± 6 years) patients, while all the other baseline demographic, clinical and biological parameters were similar between groups (Table 1) .
There were included patients with CKD stage 1 -4 (eGFR > 15 ml/min/1.73m 2 ); the distribution between CKD stages was similar between the study groups. All patients presented baseline proteinuria above 0.3 g/day; nephrotic range proteinuria was present only in 3.4% diabetic patients and in 4% patients with glomerulonephritis ( Table 2) . After one year of active treatment, all patients presented reduction of proteinuria, while renal function remained stable or even increased (Figure 1 ).
The highest percent of proteinuria reduction compared to baseline was observed in HN group (73 ± 29%), while patients with DN and GN had almost similar percent (57 ± 29%, respectively 63 ± 24%). As regards the evolution of renal function, mean eGFR presented a slight increase in patients with diabetes mellitus (0.48 ± 8 ml/min/1.73m 2 Global rate of response was 47%. Percent of responders was significantly higher (p<0.05) in the HN group (70.6%) compared to DN group (43.1%) and GN group (40%). Also, percentage of responders was higher as initial renal kidney function was better: 66.7% in CKD stage 1, 63.6% in CKD stage 2 vs 45.5% in CKD stage 3 and 25% in in CKD stage 4 (p<0.05). In our study group, none of the patients with nephrotic range proteinuria at baseline (3.4% from the total patients with DN and 4% from the total patients with GN) was able to achieve responder status (proteinuria decrease < 0.3 g/d) at the end of study (data not shown).
Mean time to achieve responder status was 8.2 ± 2.8 months. Unadjusted analysis showed a significant difference (p=0.008) between groups stratified by etiology of renal disease (Figure 2 ). In patients with HN it was noted the shortest time to response (6.6 ± 2.4 months) compared to patients with DN (8 ± 2.9 months) and GN (10.7 ± 1.2 months).
When analysed according to the baseline eGFR, a faster achievement of responder status was noted in patients with better renal function at the beginning of treatment, with significant difference (p=0.004) between different stages of CKD (Figure 3 ). Multivariate regression analysis identified that responder status was significantly associated with male gender, baseline eGFR, baseline proteinuria, and etiology of renal disease (Table 4) . Thus, the response hazard for a male is 3.948 times that of a female patient.
Also, diabetic patients have 0.445 response hazard compared to hypertensive nephropathy (p=0.015), and patients with glomerulonephritis is 0.377 of those with hypertensive nephropathy (p=0.047). Considering the impact of baseline renal function, taking CKD stage 4 as reference range, the response hazard is 3.014 times higher for a patient with CKD stage 2, and 1.688 times higher for a patient with CKD stage 3. As regards the influence of baseline proteinuria, the response hazard decreases with 60.7% for 1 gram increase in daily urinary protein loss. We also analysed the influence of ACEIs and/or ARBs treatment on the response rate and time to achieve responder status. We found no difference (p=0.836) between response rate and mean time to achieve the responder status between subgroups of patients with/without therapy acting on the RAA system (data not shown). Also, in multivariate analysis, treatment with ACEIs and/or ARBs was not found as factor that significantly influences the proteinuria reduction.
DISCUSSION
Our study showed that 12 months treatment with low-dose Sulodexide (50 mg/day) significantly reduced proteinuria in patients with CKD caused by diabetes mellitus, primary GN and HN. Mean global decrease of proteinuria level was 0.85 ± 1.34 g/day (p<0.0001), and almost half of our patients achieved responder status (final proteinuria dropped below 0.3 g/day). As glomerular filtration rate remained stable or even increased, proteinuria reduction cannot be explained by alteration of filtration capacity. Of notice, better response was achieved in patients with better renal function at baseline.
More than half of our patients had DN, which was the most studied medical condition in which Sulodexide was used. A large number of studies advocated the potential role of Sulodexide as an antiproteinuric agent in type 1 and 2 diabetes patients [11] . Since 20 years ago, Solini et al. investigated the anti-albuminuric role of Sulodexide in clinical DN [12] . In DiNAS trial, Gambaro et al. demonstrated that a 4 months course of oral Sulodexide can significantly improve either micro-or macroalbuminuria in both type 1 and type 2 diabetes mellitus, with approximately linear dose-response [13] . Maximum dose (200 mg/day) induced the highest reduction in albuminuria, effect which was sustained even after treatment cessation. More recently, DAVET study presented evidence for the efficacy of low-dose 50 mg/day Sulodexide, which was able to induce significant reduction in albuminuria when continued therapy over 12 months [14] . Likewise, our results were obtained after long-term administration of low-dose of Sulodexide.
A quarter of our patients had primary GN as cause of CKD. In this patient category, we also found significant results after Sulodexide therapy: significant proteinuria reduction (mean percentage 63 ± 24%) and slight increase in eGFR (4.16 ± 18.97 ml/min/1.73m
2 ), without any immunosuppressive therapy. Until now, only a few studies described use of Sulodexide in non-diabetic nephropathies, with conflicting results. Rozita et al. reported a significant response after 3 and 6 months of Sulodexide as rescue therapy in 16 proteinuric patients with chronic glomerulonephritis unresponsive to conventional therapies [15] . On the other hand, Bang et al. did not find a significant difference between placebo vs Sulodexide 75 mg/day and 150 mg/day administered in patient with IgA nephropathy, although the highest dose significantly reduced proteinuria [16] .
Even fewer clinical data are available on the use of Sulodexide in HN. In our patients, we unexpectedly found the best response in patients with nephroangiosclerosis due to primary hypertension: the highest percent of responders and the lowest time to response. Considering that diabetic and HN share some similar pathogenic mechanisms leading to proteinuria, like glomerular hyperfiltration and impairment of glomerular charge selectivity [17, 18] , we can thus explain the benefits of Sulodexide in this patient category.
In our study, we found that the proteinlowering effect was additive to and independent of the concomitant administration of ACEIs or/and ARBs. Similar results were described in diabetic patients from DiNAS study [12] , as well as in a pilot study reporting return to normoalbuminuria or a decrease in albumin: creatinine ratio (ACR) of at least 50% in spite of the maximum recommended dose of an ACEIs or an ARBs [19] .
Looking to the starting treatment point when Sulodexide intervention could be more efficient within CKD evolution, we found that earlier administration in the course of disease led to better outcomes. Thus, the percentage of responders progressively decreased as baseline kidney function was more impaired. As shown by experimental studies, Sulodexide has a renal protective role in mitigating glomerular sclerosis and tubulointerstitial fibrosis [19] . Once irreversible histological hallmarks of advanced CKD have been found (namely sclerosis and fibrosis), it is basically impossible to reverse the course of renal failure.
CONCLUSIONS
Our data show that low-dose long-term (12 months) treatment with Sulodexide is efficient as antiproteinuric therapy in CKD patients. A better response to this long-term low-dose Sulodexide therapy can be achieved in patients with lower degree of renal dysfunction at baseline. Apart from diabetic nephropathy, this treatment approach can induce significant benefits in patients with primary glomerulonephritis and hypertensive nephropathy. 
